Effects of prostaglandin E combined with continuous renal replacement therapy on septic acute kidney injury

Table 1 Comparison of general information

	Control group (n = 53)	Experimental group (n = 61)	t/χ2	P value
Gender (cases)			0.216	0.642
Male	38 (71.70)	42 (68.85)
Female	15 (28.30)	19 (31.15)
Age (yr)	52.64 ± 12.85	53.14 ± 12.93	0.207	0.837
BMI (kg/m2)	26.84 ± 3.42	26.94 ± 3.36	0.157	0.875
Course of disease (yr)	2.56 ± 0.58	2.67 ± 0.59	1.001	0.319
Time for intensive care unit treatment before enrollment (d)	2.13 ± 1.03	2.16 ± 1.05	0.154	0.878
Pathogenic bacteria (cases)			1.092	0.579
Gram-negative bacteria	31 (58.49)	34 (55.74)
Gram-positive bacteria	19 (35.85)	21 (34.43)
Mixed infection	3 (5.66)	6 (9.84)
Causes (cases)			0.147	0.986
Severe pancreatitis	14 (26.42)	16 (26.23)
Pneumonia	21 (39.62)	25 (40.98)
Non-suppurative cholangitis	12 (22.64)	13 (21.31)
Unknown causes	6 (11.32)	7 (11.48)
SOFA score (points)	10.38 ± 1.03	10.36 ± 1.06	0.102	0.919
APACHE II score (points)	23.91 ± 2.17	23.67 ± 2.11	0.598	0.551
RIFLE classification (cases)			0.040	0.980
Risk period	11 (20.75)	12 (19.67)
Injury period	17 (32.08)	20 (32.79)
Failure period	25 (47.17)	29 (47.54)
Diabetes (cases)			0.185	0.667
Yes	21 (39.62)	26 (42.62)
No	32 (60.38)	35 (57.38)
Hypertension (cases)			0.020	0.887
Yes	23 (43.40)	27 (44.26)
No	30 (56.60)	34 (55.74)

SOFA score: Sequential Organ Failure Assessment score; APACHE II score: Acute Physiology, Age, and Chronic Health Evaluation score; RIFLE classification: Risk, Injury, Failure, Loss, and End-stage renal failure; BMI: Body mass index.

Table 2 Comparison of disease recovery

	Control group (n = 53)	Experimental group (n = 61)	t	P value
Time for urine volume recovery (d)	14.37 ± 3.84	9.73 ± 2.91	7.324	< 0.001
Time for intensive care unit treatment (d)	18.83 ± 7.57	13.24 ± 5.26	4.625	< 0.001
Hospital stays (d)	34.53 ± 15.24	30.13 ± 14.13	1.599	0.113

Table 3 Comparison of incidence of adverse reactions, n (%)

	Control group (n = 53)	Experimental group (n = 61)	χ2	P vulue
Hypotension	2 (3.77)	2 (3.28)	-	-
Arrhythmia	2 (3.77)	1 (1.64)	-	-
Hypertension	3 (5.66)	3 (4.92)	-	-
Vomiting	2 (3.77)	3 (4.92)	-	-
Headache	2 (3.77)	1 (1.64)	-	-
Total incidence of adverse reactions	11 (20.75)	10 (16.39)	0.829	0.363